FDCDDQ
CTNM

Federation des caisses Desjardins du Quebec’s Contineum Therapeutics CTNM Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.7K Sell
1,280
-1,280
-50% -$17.2K ﹤0.01% 2148
2025
Q4 		$29.3K Hold
2,560
– – ﹤0.01% 1959
2025
Q3 		$30.1K Hold
2,560
– – ﹤0.01% 1931
2025
Q2 		$10.2K Buy
+2,560
New +$11.1K ﹤0.01% 2038

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federation des caisses Desjardins du Quebec's CTNM Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec reduced its Contineum Therapeutics (CTNM) stake by 50% in Q1 2026, selling an estimated $17.2K and leaving 1,280 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2148.

Federation des caisses Desjardins du Quebec first reported a position in CTNM in Q2 2025 and has held it in 4 quarters since. The position peaked at $30.1K in Q3 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Federation des caisses Desjardins du Quebec held 1,280 shares of Contineum Therapeutics worth $16.7K as of Q1 2026.
  • Federation des caisses Desjardins du Quebec sold 1,280 Contineum Therapeutics shares in Q1 2026, an estimated $17.2K.
  • Contineum Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2148 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Federation des caisses Desjardins du Quebec's Contineum Therapeutics position peaked at $30.1K in Q3 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.